Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Dec 17, 2022 1:52pm
153 Views
Post# 35177751

RE:RE:RE:RE:RE:RMD timing

RE:RE:RE:RE:RE:RMD timingFrom the horses mouth, so to say. As was reflected in analyst reports and from what I heard, the CEO specifically stated that was the plan and was backed by his large shareholders who felt that was the best way forward as they revise the protocol on the trial. 

palinc2000 wrote: Wino I think you have mentioned this before but what is your source of your comment that the CEO was drawing up a cost cutting plan   etc    Did you hear that from a reliable source?


Wino115 wrote: I have to assume that since CEO told his major shareholders he was drawing up both a cost cutting plan to hit breakeven as soon as possible and a plan to adjust protocal to improve try to improve efficacy in the 1b that he will announce all of that. The timing is the issue. I think the protocol would be timed to correspond with his the wider cancer advisory team and FDA given the green light, so whenever that is fully thought out. The breakeven plan could be earlier but at worst, the annual results or if they choose to release this years sales and a range for next year. Those should provide some support given it's wildly beat-up. But hard to know timing for you on that. Would it be hard to see some support and a snap-back simply because that move would reassure analysts of what they already want to hear - hard to think it won't help but whether it's 20% or 50% who knows? It's still a very illiquid situation so it works both ways. 

Lee430 wrote: Well transfer in-kind it is......gonna need to tighten the budget a bit as this WAS part of my retiremt income.

SABBOBCAT wrote:

If it you have the means, you can take the RMD in kind, can't you? Hitting the bid might not be fun before the end of the year.

 

Lee430 wrote: I need to sell about 7K shares of THTX soon for this year’s RMD, was holding out for some positive PR from Thera hoping for at least a little bump before selling…..Any thoughts on whether I should pull the trigger now or hold out a bit longer?


 









<< Previous
Bullboard Posts
Next >>